News | June 02, 2021
Progress on new ventures key for Aurobindo Pharma: ICICI Securities
Aurobindo has one of the most enduring generics ecosystems among peers
Aurobindo has one of the most enduring generics ecosystems among peers
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
Adjusted PAT declined 18.8% YoY
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
The company plans to enter the EU markets in FY22
Subscribe To Our Newsletter & Stay Updated
